Strong Buy
Average AnalystStrong Buy
Top AnalystSlightly Bullish
Stock Target AdvisorBuy
Average UserUSD 82.63
0.00 (0.00)%
USD 11.61B
2.83M
USD 85.94(+4.01%)
Symbol | Name | Exchange | GMED's Weight | Expense Ratio | Price(Change) | Market Cap |
---|---|---|---|---|---|---|
|
VanEck Bionic Engineering.. | XETRA | 4.23 % | 0.00 % | 0.00 (0.00%) | USD4.87M |
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.